首页> 美国卫生研究院文献>other >Poly(ethylene glycol)-block-poly(ε-caprolactone) Micelles for Combination Drug Delivery: Evaluation of Paclitaxel Cyclopamine and Gossypol in Intraperitoneal Xenograft Models of Ovarian Cancer
【2h】

Poly(ethylene glycol)-block-poly(ε-caprolactone) Micelles for Combination Drug Delivery: Evaluation of Paclitaxel Cyclopamine and Gossypol in Intraperitoneal Xenograft Models of Ovarian Cancer

机译:聚(乙二醇) - 嵌段 - 聚(ε-己内酯)胶束用于组合药物递送:紫杉醇环丙胺和胃型卵巢癌的卵巢血症模型的评价评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ovarian cancer is the most lethal gynecological malignancy, characterized by a high rate of chemoresistance. Current treatment strategies for ovarian cancer focus on novel drug combinations of cytotoxic agents and molecular targeted agents or novel drug delivery strategies that often involve intraperitoneal (IP) injection. Poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-b-PCL) micelles were loaded with paclitaxel (cytotoxic agent), cyclopamine (hedgehog inhibitor), and gossypol (Bcl-2 inhibitor). After physicochemical studies focusing on combination drug solubilization, 3-drug PEG-b-PCL micelles were evaluated in vitro in 2-D and 3-D cell culture and in vivo in xenograft models of ovarian cancer, tracking bioluminescence signals from ES-2 and SKOV3 human ovarian cancer cell lines after IP injection. 3-drug PEG-b-PCL micelles were not significantly more potent in 2-D cell culture in comparison to paclitaxel; however, they disaggregated ES-2 tumor spheroids, whereas single drugs or 2-drug combinations only slowed growth of ES-2 tumor spheroids or had no noticeable effects. In ES-2 and SKOV3 xenograft models, 3-drug PEG-b-PCL micelles had significantly less tumor burden than paclitaxel based on bioluminescence imaging, 3′-deoxy-3′-18F-fluorothymidine (18F-FLT) PET imaging, and overall survival. 18F-FLT-PET images clearly showed that 3-drug PEG-b-PCL micelles dramatically reduce tumor volumes over paclitaxel and vehicle controls. In summary, PEG-b-PCL micelles enable the IP combination drug delivery of paclitaxel, cyclopamine and gossypol, resulting in tumor growth inhibition and prolonged survival over paclitaxel alone. These results validate a novel treatment strategy for ovarian cancer based on drug combinations of cytotoxic agents and molecular targeted agents, delivered concurrently by a nanoscale drug delivery system, e.g. PEG-b-PCL micelles.
机译:卵巢癌是最致命的妇科恶性肿瘤,其化学耐药率很高。当前卵巢癌的治疗策略集中于细胞毒性剂和分子靶向剂的新型药物组合或通常涉及腹膜内(IP)注射的新型药物递送策略。聚(乙二醇)-嵌段-聚(ε-己内酯)(PEG-b-PCL)胶束中装载了紫杉醇(细胞毒剂),环巴胺(刺猬抑制剂)和棉酚(Bcl-2抑制剂)。经过专注于组合药物增溶的理化研究之后,在2-D和3-D细胞培养物中体外评估了3药物PEG-b-PCL胶束,在卵巢癌异种移植模型中对了3药物PEG-b-PCL胶束进行了体内评估,追踪了ES-2和IP注射后SKOV3人卵巢癌细胞系。与紫杉醇相比,3-药物PEG-b-PCL胶束在2-D细胞培养中的效力并不明显。然而,他们分解了ES-2肿瘤球体,而单一药物或2药物组合仅减慢了ES-2肿瘤球体的生长或没有明显的作用。在ES-2和SKOV3异种移植模型中,基于生物发光成像,3'-脱氧-3'- 18 F-氟胸腺嘧啶( 18 F-FLT)PET显像和整体生存率。 18 F-FLT-PET图像清楚地表明,与紫杉醇和媒介物对照相比,3-药物PEG-b-PCL胶束显着减少了肿瘤体积。总之,PEG-b-PCL胶束使紫杉醇,环巴胺和棉酚的IP组合药物递送成为可能,与单独使用紫杉醇相比,可抑制肿瘤生长并延长生存期。这些结果证实了基于细胞毒性剂和分子靶向剂的药物组合的卵巢癌的新颖治疗策略,所述药物组合物是由纳米级药物递送系统同时递送的。 PEG-b-PCL胶束。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号